Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 1
2021 1
2022 2
2023 2
2024 29
2025 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer.
Xu Y, Yang Y, Wang Z, Sjöström M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson NA, Li X, Li X, Metang LA, Mukherji A, Xu Q, Tirado CR, Wainwright G, Yu X, Barnes S, Hofstad M, Chen Y, Zhu H, Hanker AB, Raj GV, Zhu G, He HH, Wang Z, Arteaga CL, Liang H, Feng FY, Wang Y, Wang T, Mu P. Xu Y, et al. Cancer Discov. 2024 Aug 2;14(8):1496-1521. doi: 10.1158/2159-8290.CD-23-0539. Cancer Discov. 2024. PMID: 38591846 Free PMC article.
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.
Chesner LN, Polesso F, Graff JN, Hawley JE, Smith AK, Lundberg A, Das R, Shenoy T, Sjöström M, Zhao F, Hu YM, Linder S, Chen WS, Hawkins RM, Shrestha R, Zhu X, Foye A, Li H, Kim LM, Bhalla M, O'loughlin T, Kuzuoglu-Ozturk D, Hua JT, Badura ML, Wilkinson S, Trostel SY, Bergman AM, Ruggero D, Drake CG, Sowalsky AG, Fong L, Cooperberg MR, Zwart W, Guan X, Ashworth A, Xia Z, Quigley DA, Gilbert LA, Feng FY, Moran AE. Chesner LN, et al. Cancer Discov. 2025 Mar 3;15(3):481-494. doi: 10.1158/2159-8290.CD-24-0559. Cancer Discov. 2025. PMID: 39652470 Free PMC article.
RAD21 promotes oncogenesis and lethal progression of prostate cancer.
Su XA, Stopsack KH, Schmidt DR, Ma D, Li Z, Scheet PA, Penney KL, Lotan TL, Abida W, DeArment EG, Lu K, Janas T, Hu S, Vander Heiden MG, Loda M, Boselli M, Amon A, Mucci LA. Su XA, et al. Proc Natl Acad Sci U S A. 2024 Sep 3;121(36):e2405543121. doi: 10.1073/pnas.2405543121. Epub 2024 Aug 27. Proc Natl Acad Sci U S A. 2024. PMID: 39190349 Free PMC article.
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.
Dorff TB, Blanchard MS, Adkins LN, Luebbert L, Leggett N, Shishido SN, Macias A, Del Real MM, Dhapola G, Egelston C, Murad JP, Rosa R, Paul J, Chaudhry A, Martirosyan H, Gerdts E, Wagner JR, Stiller T, Tilakawardane D, Pal S, Martinez C, Reiter RE, Budde LE, D'Apuzzo M, Kuhn P, Pachter L, Forman SJ, Priceman SJ. Dorff TB, et al. Nat Med. 2024 Jun;30(6):1636-1644. doi: 10.1038/s41591-024-02979-8. Epub 2024 Jun 12. Nat Med. 2024. PMID: 38867077 Free PMC article. Clinical Trial.
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.
Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, Mikayelyan M, Delavan HM, Swinderman J, Wilson C, Zhu J, Das R, Nguyen M, Loehr A, Golsorkhi T, Simmons A, Abida W, Chinnaiyan AM, Arkin MR, Small EJ, Quigley DA, Yang L, Kim M, Ashworth A, Feng FY. Chou J, et al. Clin Cancer Res. 2024 Dec 2;30(23):5445-5458. doi: 10.1158/1078-0432.CCR-23-3785. Clin Cancer Res. 2024. PMID: 39321214 Free PMC article.
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.
Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, Nandakumar S, Kundra R, Lee C, Schultz N, Zhang J, Araujo JC, Aparicio AM, Subudhi SK, Corn PG, Pisters LL, Ward JF, Davis JW, Vazquez ES, Gueron G, Logothetis CJ, Futreal A, Troncoso P, Chen Y, Navone NM. Anselmino N, et al. Clin Cancer Res. 2024 May 15;30(10):2272-2285. doi: 10.1158/1078-0432.CCR-23-2438. Clin Cancer Res. 2024. PMID: 38488813 Free PMC article.
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Miller CD, Lozada JR, Zorko NA, Elliott A, Makovec A, Radovich M, Heath EI, Agarwal N, Mckay RR, Garje R, Bastos BR, Hoon DSB, Orme JJ, Sartor O, VanderWalde A, Nabhan C, Sledge G, Shenderov E, Dehm SM, Lou E, Miller JS, Hwang JH, Antonarakis ES. Miller CD, et al. Cancer Res Commun. 2024 May 30;4(5):1369-1379. doi: 10.1158/2767-9764.CRC-23-0546. Cancer Res Commun. 2024. PMID: 38709075 Free PMC article.
61 results